About Verge Genomics
Verge Genomics is a company based in San Francisco (United States) founded in 2015 by Jason Chen. Verge Genomics has raised $134.5 million across 4 funding rounds from investors including Lilly, WuXi AppTec and BlackRock. The company has 38 employees as of December 31, 2024. Verge Genomics offers products and services including CONVERGE Platform and VRG50635. Verge Genomics operates in a competitive market with competitors including Biogen, Insitro, BridgeBio, ATAI and Denali Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 38 as on 31 Dec, 2024
- Founders Jason Chen
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Verge Analytics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$134.5 M (USD)
in 4 rounds
-
Latest Funding Round
$98 M (USD), Series B
Dec 16, 2021
-
Investors
Lilly
& 21 more
-
Employee Count
38
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Verge Genomics
Verge Genomics offers a comprehensive portfolio of products and services, including CONVERGE Platform and VRG50635.
AI system for mapping disease causes and developing drug candidates.
Small molecule inhibitor targeting ALS and other neurological conditions.
People of Verge Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of Verge Genomics
Verge Genomics has successfully raised a total of $134.5M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $98 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Verge Genomics
Verge Genomics has secured backing from 22 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Lilly, WuXi AppTec and BlackRock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate-backed venture capital is focused on the life science sector.
|
Locked | Locked | Locked | |
|
A venture capital fund focused on biotech for neurodegeneration.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Verge Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Verge Genomics
Investment portfolio details for Verge Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Verge Genomics
Detailed financials for Verge Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Verge Genomics Comparisons
Peer comparison for Verge Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Verge Genomics
Verge Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Insitro, BridgeBio, ATAI and Denali Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Cloud-based genome informatics and data management are provided.
|
Detailed competitors of Verge Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Verge Genomics
Complete news archive for Verge Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Verge Genomics
Verge Genomics was founded in 2015.
Verge Genomics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Verge Genomics is a funded company, having raised a total of $134.5M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Verge Genomics is 38.
Verge Genomics was founded in 2015 in San Francisco, United States, within the biotechnology sector. Therapeutics for neurodegenerative diseases are developed through computational genomics, leveraging proprietary datasets from human samples. Disease-causing genes are mapped, and drugs are identified to target multiple genes concurrently. Conditions addressed include amyotrophic lateral sclerosis, Parkinsons disease, and frontotemporal dementia. Network algorithms are applied to genomic data to support this process.
Verge Genomics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Verge Genomics offers CONVERGE Platform and VRG50635.
Verge Genomics has 22 investors. Key investors include Lilly, WuXi AppTec, BlackRock, Merck Global Health Innovation Fund, and Vulcan Aerospace.